CN107249632A - 用于治疗癌症(骨髓瘤)的抗cs1与抗pd‑1抗体的组合 - Google Patents

用于治疗癌症(骨髓瘤)的抗cs1与抗pd‑1抗体的组合 Download PDF

Info

Publication number
CN107249632A
CN107249632A CN201580065674.2A CN201580065674A CN107249632A CN 107249632 A CN107249632 A CN 107249632A CN 201580065674 A CN201580065674 A CN 201580065674A CN 107249632 A CN107249632 A CN 107249632A
Authority
CN
China
Prior art keywords
antibody
cancer
tumor
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580065674.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·D·罗宾斯
R·F·格拉齐亚诺
N·彼兹曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN107249632A publication Critical patent/CN107249632A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580065674.2A 2014-12-04 2015-12-03 用于治疗癌症(骨髓瘤)的抗cs1与抗pd‑1抗体的组合 Pending CN107249632A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462087489P 2014-12-04 2014-12-04
US62/087,489 2014-12-04
PCT/US2015/063585 WO2016090070A1 (en) 2014-12-04 2015-12-03 Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)

Publications (1)

Publication Number Publication Date
CN107249632A true CN107249632A (zh) 2017-10-13

Family

ID=55022696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580065674.2A Pending CN107249632A (zh) 2014-12-04 2015-12-03 用于治疗癌症(骨髓瘤)的抗cs1与抗pd‑1抗体的组合

Country Status (13)

Country Link
US (1) US20170355768A1 (https=)
EP (1) EP3227335A1 (https=)
JP (1) JP2017537927A (https=)
KR (1) KR20170088984A (https=)
CN (1) CN107249632A (https=)
AU (1) AU2015358462A1 (https=)
BR (1) BR112017011538A2 (https=)
CA (1) CA2969665A1 (https=)
EA (1) EA201791049A1 (https=)
IL (1) IL252535A0 (https=)
MX (1) MX2017007097A (https=)
SG (1) SG11201704343SA (https=)
WO (1) WO2016090070A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103282359A (zh) 2010-12-17 2013-09-04 诺华股份有限公司 5-氯-n2-(2-异丙氧基-5-甲基-4-哌啶-4-基-苯基)-n4-[2-(丙烷-2-磺酰基)-苯基]-嘧啶-2,4-二胺的结晶形式
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
AU2013337903B2 (en) 2012-10-30 2018-08-16 Apexigen, Inc. Anti-CD40 antibodies and methods of use
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
AU2017353852A1 (en) * 2016-11-02 2019-05-23 Apexigen, Inc. Anti-CD40 antibodies in combination and methods of use
US20210155691A1 (en) * 2018-04-16 2021-05-27 Adaerata, Limited Partnership Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960750A (zh) * 2004-03-29 2007-05-09 Pdl生物制药公司 抗cs1抗体的治疗用途
CN101686971A (zh) * 2006-08-07 2010-03-31 菲赛特生物技术公司 使用基于抗cs1-抗体的联合疗法治疗多发性骨髓瘤的方法
CN102216332A (zh) * 2008-10-31 2011-10-12 艾伯特生物治疗学公司 抗-cs1抗体用于治疗罕见淋巴瘤的用途
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
DK1141028T3 (da) 1998-12-23 2010-05-25 Pfizer Humane monoklonale antistoffer til CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
BR0008379A (pt) 1999-02-22 2002-09-24 Biotechnolog Forschung Gmbh Epotilonas modificadas em c-21
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
US7041499B2 (en) 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US6958115B2 (en) 2003-06-24 2005-10-25 The United States Of America As Represented By The Secretary Of The Navy Low temperature refining and formation of refractory metals
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US20080095768A1 (en) 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
JP2010500370A (ja) 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US20130058921A1 (en) 2009-10-30 2013-03-07 Frits VAN RHEE Use of autologous effector cells and antibodies for treatment of multiple myeloma
US20130052158A1 (en) 2009-10-30 2013-02-28 University Of Arkansas For Medical Science Use of autologous effector cells for treatment of multiple myeloma
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960750A (zh) * 2004-03-29 2007-05-09 Pdl生物制药公司 抗cs1抗体的治疗用途
CN101686971A (zh) * 2006-08-07 2010-03-31 菲赛特生物技术公司 使用基于抗cs1-抗体的联合疗法治疗多发性骨髓瘤的方法
CN102216332A (zh) * 2008-10-31 2011-10-12 艾伯特生物治疗学公司 抗-cs1抗体用于治疗罕见淋巴瘤的用途
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Also Published As

Publication number Publication date
JP2017537927A (ja) 2017-12-21
WO2016090070A1 (en) 2016-06-09
MX2017007097A (es) 2017-09-05
CA2969665A1 (en) 2016-06-09
BR112017011538A2 (pt) 2018-03-13
EP3227335A1 (en) 2017-10-11
SG11201704343SA (en) 2017-06-29
IL252535A0 (en) 2017-07-31
EA201791049A1 (ru) 2017-10-31
AU2015358462A1 (en) 2017-07-27
US20170355768A1 (en) 2017-12-14
KR20170088984A (ko) 2017-08-02

Similar Documents

Publication Publication Date Title
US20220184209A1 (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
KR102870759B1 (ko) 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
KR102515509B1 (ko) 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
CN107249632A (zh) 用于治疗癌症(骨髓瘤)的抗cs1与抗pd‑1抗体的组合
JP2023085370A (ja) 免疫調節剤を併用するがんの治療
KR102867506B1 (ko) 퀴놀린 유도체 및 항체의 약물 조합
US20220324965A1 (en) Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20160264670A1 (en) Immunotherapeutic dosing regimens and combinations thereof
JP2019526273A (ja) Ｐｄ−ｌ１及びｌａｇ−３に結合する結合分子
CN114432440A (zh) 使用抗pd-1抗体与另一抗癌剂的组合治疗肾癌
CN104470949A (zh) 通过破坏pd-1/pd-l1信号传输的免疫治疗
KR20110013423A (ko) 보조자극 경로의 조절에 대한 환자 반응을 예측하는 방법
BR112020023026A2 (pt) anticorpos completamente humanos contra ox40, método para a sua preparação e sua utilização
US20210154183A1 (en) Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
WO2017070137A1 (en) Combination of ck2 inhibitors and immune checkpoint modulators for cancer treatment
US11040223B2 (en) Compositions and methods related to xCT peptides
CN117603360A (zh) 用于治疗癌症的多特异性抗体
KR20260021654A (ko) Ctla4를 표적화하는 약물 접합체, 이를 포함하는 제품, 및 이의 치료적 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171013